Bioarctic granted Japanese patent for Parkinson’s disease candidate

Bioarctic has been granted a Japanese patent for its antibodies targeting Parkinson’s disease.

Tirzepatide approved for obesity by the FDA – to be branded as Zepbound

Diabetes drug tirzepatide has now also been approved in the US for treating obesity.

Samuel Lagercrantz: A special kind of hellishness afflicts post-COVID patients

In addition to the disease itself those suffering from post-COVID have to deal with people who try to label them as hypochondriacs, writes Samuel Lagercrantz in an editorial.

Mastering Urine Microscopy: Techniques for Accurate Disease Detection

Live Webinar on September 25, 2024.

Astra Zeneca's Covid-19 vaccine Vaxzevria is being withdrawn worldwide

AstraZeneca initiates a worldwide withdrawal of its Covid vaccine Vaxzevria. The measure is taken just months after the company admitted the vaccine can cause a...

Samuel Lagercrantz: ”Will the Swedish life science strategy be updated with precision?”

What will the Swedish government focus on in the life science strategy that is being updated? And what should be prioritized in the strategy? Life Science Swede...

Lonza

The fast route to a safe insulin pen

Diabetes is on the rise worldwide with around ten million people developing the disease every year. Demand for insulin pens allowing patients to self-medicate i...

How to optimise your liquid handling results

In dispensing or pipetting applications in laboratory automation, it is important to obtain reliable results, which are analysed by calculating the accuracy and...

SGS Fimko Ltd.

Astra Zeneca’s Sweden CEO: “We have great faith in our portfolio”

It all started with a summer job as an operator at Astra’s chemical factory in Snäckviken, just outside Södertälje. More than three decades and countless differ...

A new special edition and a new event in Copenhagen – This is happening at Life Science Sweden 2024

The new year brings new features for the readers of Life Science Sweden.

Fundamental Aspects of Airy Disk Patterns

Knowledge Article from ZEISS.

Settlement of cancer allegations against blockbuster drug

French pharmaceutical company Sanofi has reached a principal agreement in the US on around 4,000 of the cases in which its now withdrawn blockbuster heartburn d...

Anna Törner: Vem betalar för Rebecca Doe – och alla oss andra?

Det lätt att vänja sig vid tanken att vård och läkemedel är gratis, när det egentligen handlar om hur och vem som betalar. Det skriver Anna Törner i en krönika.

MSD discontinues development of cancer drugs after trial failures

MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.

Study names with an attitude – more important than you might think

Ironman, T-rex, Star-Trek. Popcorn, Proper, Scout. Nope, these are neither fantasy films nor dog names. They’re the names of ongoing cancer studies in Sweden.

Truly Labs AB

Pfizer slutar sälja uppmärksammad genterapi

Pfizer kommer att avbryta utvecklingen och försäljningen av sin uppmärksammade och extremt dyra genterapi mot blödarsjuka, Beqvez. Orsaken uppges vara bristande efterfrågan.

Nanexa develops depot formulation of the diabetes and obesity drug Saxenda

Uppsala-based company Nanexa has signed an agreement with a German contract research company to start a clinical study with a monthly depot of liraglutide. The ...

Quattroflow Q-Control - Smart styrning av pumpdrift i din bioprocessanläggning.

Quattroflow är en hermetisk pump utan axeltätningar som ger ett pulsationsfritt, kontrollerat och reglerbart flöde utan återläckage. Quattroflow är utvecklad fö...

Smart styrning av pumpdrift i din bioprocessanläggning - Quattroflow Q-Control

Q-Control är en integrerad pumpstyrning (PID-regulator) för Quattroflow Multi-Use och Single-Use pumpar.

One last chance to register for the premier metrology event in 2024

ZEISS QUALITY INNOVATION SUMMIT.

Just four weeks to a concept for an emergency ventilator

The lockdown in spring 2020 meant that the majority of Festo employees had to join the ranks of those working from home. Yet within the space of just four weeks...